NO | 제품 | CAS NO | 주요 품질 표시기 | |||
청정 | 맥스. 불결 | 총 용매 잔류 물 | 수분 | |||
1 | FMOC-β-ALA-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | fmoc-d-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | FMOC-β-ALA-D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | FMOC-ARG (PBF) -ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | FMOC-β-ALA-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | fmoc-d-arg (pbf) -d-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | FMOC-HOMOARG (PBF) -homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | FMOC-β-ALA-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | fmoc-asn (trt) -asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | fmoc-asp (otbu) -asp (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | FMOC-β-ALA-ASP (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | fmoc-cys (trt) -cys (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | FMOC-β-ALA-CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | fmoc-cys (acm) -cys (ACM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | FMOC-β-ALA-CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | FMOC-GLN (TRT) -GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | fmoc-glu (otbu) -glu (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | FMOC-β-ALA-GLU (OTBU) -OH.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | FMOC-β-ala-Gly-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | FMOC-HIS (TRT) -HIS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | FMOC-β-ALA-HIS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | FMOC-ILE-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | FMOC-β-ala-Ile-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | FMOC-LEU-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | FMOC-β-ALA-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | FMOC-D-LEU-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | FMOC-β-ALA-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | fmoc-lys (boc) -lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | FMOC-β-ALA-LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | fmoc-lys (alloc) -lys (alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | fmoc-β-ala-lys (Alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | FMOC-Met-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | FMOC-β-ALA-MET-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | fmoc-orn (boc) -orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | FMOC-β-ALA-ER (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | FMOC-β-ALA-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | FMOC-β-ALA-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | FMOC-β-ALA-PO-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | fmoc-ser (tbu) -ser (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | FMOC-β-ALA-SER (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | fmoc-ser (trt) -ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | FMOC-β-ALA-SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | FMOC-β-ALA-THR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | fmoc-trp (boc) -trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | FMOC-β-ALA-TYR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | fmoc-d-tyr (et) -d-tyr (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | fmoc-tyr (me) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | fmoc-β-ala-tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | FMOC-VAL-VAL-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | FMOC-β-ALA-VAL-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | FMOC-β-ALA-DAB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | FMOC- (3- (2- 나프 틸) -D-ALA) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | FMOC-β-ALA-3- (2- 나프 틸) -D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | FMOC- (3- (3- 피리 디 닐) -D-ALA) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | FMOC-β-ALA-3- (3- 피리 디 닐) -D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | FMOC- (4- 클로로 -D-PHE) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | FMOC-β-ALA-4- 클로로 -D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | fmoc-aph (l-hor) -aph (l-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | FMOC-β-ALA-APH (L-HOR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | fmoc-lys (ipr, boc) -lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | FMOC-β-ALA-LYS (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | FMOC-β-ALA-EAEA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | FMOC-AIB-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | FMOC-β-ALA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | FMOC-ARG-OH | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H-ARG (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | FMOC-D-ARG-OH | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | FMOC-HOMOARG-OH.HCL | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | H-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | FMOC-D-HOMOARG-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | HD-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | FMOC-ASN-OH | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | FMOC-ASP-OH | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | h-asp (otbu) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | FMOC-CYS-OH | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | h-cys (trt) -oh | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-Cys (ACM) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | FMOC-GLN-OH | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | H-Glu (OTBU) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | FMOC-HIS-OH | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | H-HIS (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | FMOC-LYS-OH | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-Lys (BOC) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-Lys (Alloc) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | fmoc-orn-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | h-nor (Boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | FMOC-SER-OH | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-Ser (TBU) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-Ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | H-THR (TBU) -OH | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | FMOC-TRP-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
114 | H-TRP (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | FMOC-TYR-OH | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | H-Tyr (TBU) -OH | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | fmoc-d-tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | HD-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | h-tyr (me) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | hd-4aph (tbucbm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | fmoc-lys (ipr) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-Lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
보상
Gentolex는 훌륭한 품질의 제품을 제공합니다. 필요한 기간 내에 고객이 제품 품질을 충분히 증명하여 제기하면 보상 절차를 트리거하는 데 필요한 분석 및 평가를 제공 할 것입니다.
생산
제약 제품의 능력은 톤 등급에 도달했으며 화학 제품의 역량은 100tons+ 등급에 도달하며 기능은 전 세계 고객에게 서비스를 제공 할 수있는 장비가 잘 갖추어져 있습니다.
연구 개발
매년 R & D 팀이 다양한 신제품을 개발할 계획이 있으며, 목표가 설정되면 팀의 모든 구성원은 KPI 책임과 인센티브 정책을 수행해야합니다.